share_log
Moomoo 24/7 ·  Apr 24 07:33
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of Aro-Cfb for Treatment of Complement Mediated Kidney Disease
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment